We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
- Authors
De Luca, Rossella; Costa, Renato Patrizio; Tripoli, Vincenzo; Murabito, Alessandra; Cicero, Giuseppe
- Abstract
<bold><italic>Background/Aim:</italic></bold> Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. <bold><italic>Subjects and Methods:</italic></bold> In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. <bold><italic>Results:</italic></bold> Radium-223 was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum ALP levels before and after treatment was observed, with a significant correlation between pain relief and QoL, which showed a value of <italic>R</italic>2 to 0.44 with a slope of 1.50 (<italic>p</italic> = 0.0021). <bold><italic>Conclusions:</italic></bold> Radium-223 showed a clinical benefit, with a reduction in pain symptoms in 58% of patients. Radium-223 was shown to be an effective and well-tolerated therapeutic option in patients with metastatic CRPC progressing after docetaxel plus prednisone treatment.
- Subjects
ITALY; RADIUMTHERAPY; PREDNISONE; DOCETAXEL; ALKALINE phosphatase; BONE metastasis; BONES; CANCER patient psychology; COMBINATION drug therapy; PAIN; PROSTATE tumors; QUALITY of life; TOXICITY testing; TREATMENT effectiveness; RETROSPECTIVE studies
- Publication
Oncology, 2018, Vol 94, Issue 3, p161
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000485102